More on ENTX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.92 |
|
|||
| Open | $3.90 | ||||
| 52 Wk High | $0.30 | ||||
| 52 Wk Low | $0.10 | ||||
| Day High | $3.96 | ||||
| Day Low | $3.02 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 4,892,119 | ||||
- Entera Bio prices $275M private placement led by BVF Partners
- Entera Bio prices $275 million private placement led by BVF Partners
- Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
- Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
- Form 8-K Entera Bio Ltd. For: Jul 14
- Form 4 Entera Bio Ltd. For: Jul 14 Filed by: Toledano Miranda Jayne
- H.C. Wainwright Reiterates Buy Rating on Entera Bio (ENTX)
- FDA backs Entera Bio's Phase 3 trial plan for oral osteoporosis drug
- Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
- ENTERA BIO shares preclinical data for two pipeline drugs at ENDO 2026
Entities mentioned with ENTX
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Layoffs | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
